CD5 and mantle cell lymphoma: Mantle cell lymphoma (MCL) is a CD5-positive, CD23-negative B cell malignancy accounting for 6% of all non-Hodgkin lymphomas (NHL) and carries a poor prognosis, with a median survival of only 4–5 years.